Skip to main content

Table 1 The primary outcome

From: Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review

   n
KQ 1 Does rebiopsy in the 1st or 2nd generation EGFR-TKI refractory patients improve prognosis? 1
KQ 2 What are the rebiopsy samples? 98
KQ 3 How are EGFR gene mutations detected? 93
KQ 4 Is the benefit of liquid biopsy greater than the harm? 1
KQ 4’ Is the benefit of tissue rebiopsy greater than the harm? 8
KQ 5 How often is T790M mutation detected in the 1st or 2nd generation EGFR-TKI refractory cases? 99
KQ 6 How is the prognosis when the 3rd generation EGFR- TKI is administered to T790M positive cases? 11
KQ 7 Is the benefit of the 3rd generation EGFR-TKI to T790M positive cases greater than the harm? 1
KQ 8 How is the prognosis of T790M negative cases? 29
KQ 9 How is the prognosis when rebiopsy is not performed in the 1st or 2nd generation EGFR-TKI refractory cases? 1
  1. The key questions (KQs) and the number of articles which answer to each KQ are shown
\